SCHEMBL520960

SCHEMBL520960

CC(C)(C)OC(=O)N1CCN(c2cccc3cc(I)cnc23)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
BACE1 P56817 2/20 0.46
MAP4K4 O95819 1/20 0.45
KIT P10721 2/20 0.45
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
ACHE P22303 2/20 0.44
PTPN11 Q06124 1/20 0.44
GPR119 Q8TDV5 1/20 0.43
MET P08581 1/20 0.42
POLB P06746 1/20 0.42
RET P07949 1/20 0.42
CYP11B2 P19099 1/20 0.41
PARP1 P09874 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520241 0.87 MAP4K4 (0.50) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL3917828 0.83 MAPT (0.43) GPR119POLBRETMEN1MAPT
SCHEMBL4800091 0.83 CKS1B (0.51) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL1048457 0.82 POLB (0.55) CKS1BSKP1SKP2MAP4K4SMARCA2
SCHEMBL2197307 0.81 HTR2A (0.63) CKS1BSKP1SKP2BACE1KIT
SCHEMBL4800390 0.80 MAPT (0.45) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL2854558 0.80 HRH1 (0.47) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL2878178 0.80 KMT2A (0.49) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL4701379 0.80 TGM2 (0.47) CKS1BSKP1SKP2GPR119MET
SCHEMBL2878173 0.80 KMT2A (0.49) CKS1BSKP1SKP2BACE1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed
EP-2027108-B1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LTD (GB) 2010-01-13 EP disclosed
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core GLAXO GROUP LIMITED (GB) 2009-07-16 US disclosed
EP-2027108-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE Glaxo Group Limited (GB) 2009-02-25 EP disclosed
WO-2007135081-A1 HISTAMINE RECEPTOR ANTAGONISTS COMPRISING AN AZEPIN CORE GLAXO GROUP LIMITED (GB) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181950-A1 Histamine Receptor Antagonists Comprising an Azepin Core HRH2, HRH1, HRH4 CKS1B 3425/4885SKP1 2171/4885SKP2 2244/4885
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 CKS1B 464/4885SKP1 161/4885SKP2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.